Table 2.

Analysis of End Points Without Baseline Measurements

End PointMean Value During the
12 Weeks of Treatment*
Least-Square Mean (95% CI) Difference Between GroupsP Value
PlaceboMontelukast
Days with daytime asthma symptoms (%)6459−5.57 (−9.91 to −1.23).012
Days with β-agonist use (%)5549−6.25 (−10.06 to −2.43).001
Patients requiring oral corticosteroid rescue (%)2819.008
Patients experiencing ≥1 asthma attack (%)3226.107
Days without asthma (%)2834 6.87 (2.60 to 11.13).002
Physician global evaluation score1.381.11−0.27 (−0.47 to −0.07).007
Caregiver global evaluation score1.120.97−0.16 (−0.35 to 0.03).107
Average global evaluation score1.271.05−0.23 (−0.41 to −0.04).015
  • CI indicates confidence interval.

  • * Global evaluations were performed at the end of the treatment period. All other end points are mean values during treatment.